表纸
市场调查报告书

全球抗逆转录病毒药市场:成长,趋势,预测

Anti-retroviral Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 391438
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
Back to Top
全球抗逆转录病毒药市场:成长,趋势,预测 Anti-retroviral Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

本报告提供全球抗逆转录病毒药市场相关调查,提供市场趋势与今后的成长预测,汇整各产品,各地区趋势,及打入市场的主要企业简介等资讯。

第1章 简介

第2章 调查方法

第3章 摘要整理

第4章 主要推论

第5章 市场趋势

  • 推动市场的要素
  • 阻碍市场的要素
  • 市场机会
  • 课题
  • 波特五力分析

第6章 市场区隔

  • 抗逆转录病毒
    • 蛋白分解酵素抑制剂
    • 非核苷酸逆转录抑制剂
    • 核苷酸类比及核苷酸逆转录抑制剂
    • Integrase抑制剂
    • 其他

第7章 各地区占有率及预测

  • 北美
  • 欧洲
  • 亚太地区
  • 中东·非洲
  • 南美

第8章 竞争环境

  • 新产品上市
  • 合并·收购
  • 协定,联合,联盟

第9章 企业简介

第10章 投资的机会相关分析师预测

第11章 市场未来发展预测

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 46540

Antiretroviral are the drugs that treat HIV. Factors contributing to the growth of the market includes rising burden of HIV, increasing investment in R&D and increase in availability of novel drugs with better efficacy. According to the U.S. Department of Health & Human Services, there were approximately 37.9 million people worldwide that were living with HIV/AIDS. An estimated 1.7 million individuals worldwide became newly infected with HIV in 2018. Anti-retrovirals (ARVs) are the foundation of HIV/AIDS management, as currently there is no cure or vaccine available for HIV. In individuals with a non-resistant strain of HIV, the antiretroviral treatment can suppress the replication of HIV in about 80% of cases. This huge patient pool shows that the market for anti-retroviral drugs is expected to grow in the forecast period.

Key Market Trends

Multi-class Combination Products is Expected to Register a Significant Growth in the Forecast Years

Based on drug class, it is segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Others. The key factor contributing to the growth of the Multi-class Combination Products is the rising burden of HIV and new drug approval. According to WHO, around 770,000 people died from HIV in 2018. Many companies are focusing on developing breakthrough products for the treatment of antiretroviral drugs in order to maintain their competitive advantage and penetrate new regional markets. Additionally, the increase in funding for companies involved in the research related to anti-retroviral drugs is expected to boost the studied market.

North America holds the Largest Share in the Anti-retroviral Drugs Market

The Anti-retroviral Drugs market holds the largest share in the North America region. According to the U.S. Department of Health & Human Services, it is estimated that there are over 56,000 new cases of HIV in the United States each year and about 20 in 100 infected Americans do not know they have the virus. The growth is attributed to a high ART coverage rate and rising emphasis on prescribed branded drugs. In addition, the National Institutes of Health (NIH), United States, represents the largest public investment in HIV/AIDS research in the world, which is expected to fuel the market growth.

Competitive Landscape

The present demand of companies in the anti-retroviral segment is improving upon its research and development capabilities via collaboration, merger, and acquisition, as well as exploring new geographic regions. The global players in the anti-retroviral drugs market are - AbbVie Inc., Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Merck & Co, Inc., Mylan N.V., and ViiV Healthcare.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of HIV
    • 4.2.2 Increasing Investment in R&D
    • 4.2.3 Increase in Availability of Novel Drugs with Better Efficacy
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Protease Inhibitors
    • 5.1.2 Integrase Inhibitors
    • 5.1.3 Multi-class Combination Products
    • 5.1.4 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 5.1.5 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 5.1.6 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Boehringer Ingelheim International GmbH
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Gilead Sciences, Inc.
    • 6.1.6 Merck & Co, Inc.
    • 6.1.7 Mylan N.V.
    • 6.1.8 ViiV Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top